Abstract
Improved survival achieved by HIV-infected patients has complicated their medical care, as increasing numbers of comorbidities have led to polypharmacy and a higher risk of drug-drug interactions. Here, evidence is provided that weight-loss drugs should be used with caution in HIV-infected patients treated with lipophilic antiretroviral drugs because of the risk of virologic failure. This is particularly relevant considering that these agents are available on the market as over-the-counter medications, thus escaping the control of the physician.
© 2018 The Obesity Society.
MeSH terms
-
Adult
-
Anti-Obesity Agents / adverse effects*
-
Anti-Obesity Agents / therapeutic use
-
Anti-Retroviral Agents / antagonists & inhibitors*
-
Anti-Retroviral Agents / therapeutic use
-
Cohort Studies
-
Comorbidity
-
Disease Progression
-
Drug Antagonism
-
Female
-
HIV / drug effects
-
HIV / physiology
-
HIV Infections / drug therapy
-
HIV Infections / epidemiology
-
HIV Infections / pathology
-
HIV Infections / virology*
-
Humans
-
Nonprescription Drugs / adverse effects*
-
Nonprescription Drugs / therapeutic use
-
Polypharmacy
-
Preliminary Data
-
Treatment Failure
-
Viremia / drug therapy
-
Viremia / pathology*
Substances
-
Anti-Obesity Agents
-
Anti-Retroviral Agents
-
Nonprescription Drugs